Abhishek Rana
About Abhishek Rana
Abhishek Rana has 4 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including Hedvuk Private Limited and Wraaim Technologies Llp. Formerly with 2 companies, such as Alegion Health Tech Private Limited and Destratum Solutions Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Hedvuk Private Limited
U34300TZ2021PTC036779
|
Director | 10 Aug 2021 | 2021 | Active |
Wraaim Technologies Llp
ABB-9788
|
Designated Partner | 03 Aug 2022 | 2022 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Alegion Health Tech Private Limited
U86900TN2024PTC172017
|
Director | 19 Jul 2024 | 2024 | Active |
Destratum Solutions Private Limited
U72200TN2022PTC149066
|
Director | 07 Jan 2022 | 2022 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Abhishek Rana
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Abhishek Rana
Abhishek Rana has 4 years in corporate governance. Holds Director and Designated Partner roles. Currently with 2 companies, including Hedvuk Private Limited and Wraaim Technologies Llp. Formerly with 2 companies, such as Alegion Health Tech Private Limited and Destratum Solutions Private Limited. Engaged in General Business, Technology. Contributes to corporate operations.
Abhishek Rana is associated with 2 companies as Director and Designated Partner.
Abhishek Rana has expertise in General Business, Technology.
Abhishek Rana has 4 years in corporate governance.